Prediction of axillary lymph node involvement of women with invasive breast carcinoma: A multivariate analysis

Cancer

Volumn 83, Issue 5, 1998, Pages 948-955

  Olivotto, Ivo A ^a,d   Jackson, Jeremy S H ^a,b   Mates, Donna ^a   Andersen, Sandra ^a,c   Davidson, Warren ^a,d   Bryce, Cicely J ^a,d   Ragaz, Joseph ^a,d  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b Fraser Valley Cancer Centre   (Canada)

^c Vancouver Island Cancer Center   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Adjuvant therapy; Axillary lymph node dissection; Breast neoplasm; Multivariate analysis; Nodal metastases; Prediction

Indexed keywords

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CARCINOMA; CANCER INVASION; CANCER SIZE; CANCER STAGING; FEMALE; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MAMMOGRAPHY; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; ANALYSIS OF VARIANCE; AXILLA; BREAST NEOPLASMS; FEMALE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; MODELS, THEORETICAL; MULTIVARIATE ANALYSIS; REGRESSION ANALYSIS;

EID: 0032169044     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980901)83:5<948::AID-CNCR21>3.0.CO;2-U     Document Type: Article

References (35)

1. Fisher B, Redmond C, Fisher ER, Bauer M, Wolmark N, Wickerham L, et al. Ten year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med 1985;312:674-81.
2. Bonadonna G, Brusamolino E, Valagussa P, Rossi A, Brugnatelli L, Brambilla C, et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 1976;294:405-10.
3. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy: 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992;399:1-15,71-85.
4. Recht A, Houlihan MJ. Axillary lymph nodes and breast cancer: a review. Cancer 1995;76:1491-512.
5. Goldhirsh A, Wood WC, Senn JH, Gelber RD. International consensus conference on primary treatment of breast cancer. Recent Results Cancer Res 1996;140:325-35.
6. Anonymous. Treatment of early-stage breast cancer. National Institute of Health Consensus Development Conference. JAMA 1991;265:391-5.
7. Hladiuk M, Huchcroft S, Temple W, Schnurr Be. Arm function after axillary dissection for breast cancer: a pilot study to provide parameter estimates. J Surg Oncol 1992;50:47-52.
8. Liljegren G, Holmberg L, Uppsala-Orebro Breast Cancer Study Group. Arm morbidity after sector resection and axillary dissection with or without postoperative radiotherapy in breast cancer stage I. Results from a randomized trial. Eur J Cancer 1997;33:193-9.
9. Aitken RJ, Gaze MN, Rodger A, Chetty U, Forrest APM. Arm morbidity within a trial of mastectomy and either nodal sample with selective radiotherapy or axillary clearance. Br J Surg 1989;76:568-71.
10. Keramopoulos A, Tsionou C, Minaretzis D, Michalas S, Aravantinos D. Arm morbidity following treatment of breast cancer with total axillary dissection: a multivariated approach. Oncoloy 1993;50;445-9.
11. Fentiman IS, Epstein R, Barr L. Is routine axillary nodal dissection necessary in the treatment of breast cancer? Eur J Cancer 1996;32A:1460-3.
12. Cady B. Use of primary breast carcinoma characteristics to predict lymph node metastases. Cancer 1997;79:1856-61.
13. Giuliano AE, Jones RC, Brennan M, Statman R. Sentinel lymphadenectomy in breast cancer. J Clin Oncol 1979;15: 2345-50.
14. Veronesi U, Paganelli G, Galimberti V, Viale G, Zurrida S, Bedoni M, et al. Sentinal-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymphnodes. Lancet 1997;349:1864-7.
15. Chadha M, Chabon AB, Friedmann P, Vikram B. Predictors of axillary lymph node metastases in patients with T1 breast cancer: a multivariate analysis. Cancer 1994;73:350-3.
16. Ahlgren J, Stal O, Westman AG, Arnesson LG. Prediction of axillary lymph node metastases in a screened breast cancer population. Acta Oncologica 1994;33:603-8.
17. De Laurentiis M, Gallo C, De Placido S, Perrone F, Pettianato G, Petrella G, et al. A predictive index of axillary nodal involvement in operable breast cancer. Br J Cancer 1996;73: 1241-7.
18. Barth A, Craig PH, Silverstein MJ. Predictors of axillary lymph node metastases in patients with T1 breast carcinoma. Cancer 1997;79:1918-22.
19. Choong PL, deSilva CJS, Dawkins HJS, Sterrett GF, Bobbins P, Harvey JM, et al. Predicting axillary lymph node metastases in breast carcinoma patients. Breast Cancer Res Treat 1996;37:135-49.
20. Fein Da, Fowble BL, Hanlon AL, Hooks MA, Hoffman JP, Sigurdson ER, et al. Identification of women with T1-T2 breast cancer at low risk of positive lymph nodes. J Surg Oncol 1997;65:34-9.
21. Mustafa IA, Cole B, Wanebo HJ, Bland KI, Chang HR. The impact of histopathology on nodal metastases in minimal breast cancer. Arch Surg 1997;132:384-90.
22. Ravdin PM, De Laurentiis M, Vendely T, Clark GM. Prediction of axillary lymph node status in breast cancer patients by use of prognostic indicators. J Natl Cancer Inst 1994;86: 1771-5.
23. Chu KC, Tarone RE, Kessler LG, Ries LAG, Hankey BF, Miller BA, Edwards BK. Recent trends in U.S. breast cancer incidence, survival and mortality rates. J Natl Cancer Inst 1996; 88:1571-9.
24. Quinn M, Allen E. Changes in incidence of and mortality from breast cancer in England and Wales since introduction of screening. Br Med J 1995;311:1391-5.
25. Clay MG, Hislop TG, Kan L, Olivotto IA, Warren Burhenne LJ. Screening mammography in British Columbia: 1988-1993. Am J Surg 1994;167:490-2.
26. Olivotto IA, Bajdik CD, Plenderleith IH, Coppin CM, Gelmon KG, Jackson SM, et al. Adjuvant systemic therapy and survival after breast cancer. N Engl J Med 1994;330:805-10.
27. Olivotto IA, Goldman AJ, Hislop TG, Trevisan CH, Kula J, Goel V, et al. Compliance with practice guidelines for node-negative breast cancer. J Clin Oncol 1997;15:216-22.
28. Hermanek P, Sobin LH, editors. UICC TNM classification of malignant tumors, 4th ed, 2nd rev. Berlin: Springer-Verlag, 1992.
29. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer: I. The value of histopathological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991;19:403-10.
30. ICD-O. International classification of diseases for oncology, 2nd ed. Geneva: World Health Organization, 1990.
31. Homer DW, Lemeshow S. A goodness of fit test for the multiple logistic regression model. Commun Statistics 1980; 10:1043-69.
32. Koscielny S, Le MG, Tubiana M. The natural history of human breast cancer. The relationship between involvement of axillary lymph nodes and the initiation of distant metastases. Br J Cancer 1989;59:775-82.
33. Carter CL, Allen C, Henson D. Relation of tumor size, lymph node status and survival in 24,740 breast cancer cases. Cancer 1989;63:181-7.
34. Breast Tumour Group. Cancer treatment policies, 5th ed. Vancouver: British Columbia Cancer Agency, 1992 and 1996.
35. Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings of the National Surgical Adjuvant Breast and Bowel Project protocol B18. J Clin Oncol 1997;15:2483-93.